Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection.
bivalent ligands
dopamine
dopamine D3 receptor
heteromerization
neuroplasticity
neuroprotection
nicotinic acetylcholine receptor
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
09 07 2020
09 07 2020
Historique:
received:
28
05
2020
revised:
06
07
2020
accepted:
08
07
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
17
4
2021
Statut:
epublish
Résumé
The dopamine (DA) D3 receptor (D3R) plays a pivotal role in the control of several functions, including motor activity, rewarding and motivating behavior and several aspects of cognitive functions. Recently, it has been reported that the D3R is also involved in the regulation of neuronal development, in promoting structural plasticity and in triggering key intracellular events with neuroprotective potential. A new role for D3R-dependent neurotransmission has thus been proposed both in preserving DA neuron homeostasis in physiological conditions and in preventing pathological alterations that may lead to neurodegeneration. Interestingly, there is evidence that nicotinic acetylcholine receptors (nAChR) located on DA neurons also provide neurotrophic support to DA neurons, an effect requiring functional D3R and suggesting the existence of a positive cross-talk between these receptor systems. Increasing evidence suggests that, as with the majority of G protein-coupled receptors (GPCR), the D3R directly interacts with other receptors to form new receptor heteromers with unique functional and pharmacological properties. Among them, we recently identified a receptor heteromer containing the nAChR and the D3R as the molecular effector of nicotine-mediated neurotrophic effects. This review summarizes the functional and pharmacological characteristics of D3R, including the capability to form active heteromers as pharmacological targets for specific neurodegenerative disorders. In particular, the molecular and functional features of the D3R-nAChR heteromer will be especially discussed since it may represent a possible key etiologic effector for DA-related pathologies, such as Parkinson's disease (PD), and a target for drug design.
Identifiants
pubmed: 32659920
pii: biom10071016
doi: 10.3390/biom10071016
pmc: PMC7407647
pii:
doi:
Substances chimiques
Receptors, Dopamine D3
0
Receptors, Nicotinic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Transl Neurodegener. 2017 Jul 2;6:18
pubmed: 28680589
ACS Chem Biol. 2008 Nov 21;3(11):677-692
pubmed: 19112665
PLoS One. 2015 Jun 18;10(6):e0130572
pubmed: 26086615
Eur Neuropsychopharmacol. 2017 Apr;27(4):313-324
pubmed: 28187919
CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43
pubmed: 16613552
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):651-8
pubmed: 21838678
J Neural Transm (Vienna). 2007 Jan;114(1):135-47
pubmed: 16906354
Addict Biol. 2007 Mar;12(1):35-50
pubmed: 17407496
J Neurosci. 2003 Aug 27;23(21):7820-9
pubmed: 12944511
Nature. 1997 Nov 27;390(6658):401-4
pubmed: 9389479
Mol Neurobiol. 2019 Oct;56(10):6756-6769
pubmed: 30919214
J Biol Chem. 2008 Sep 19;283(38):26016-25
pubmed: 18644790
Mol Pharmacol. 2005 Feb;67(2):400-7
pubmed: 15539641
Neuroscience. 2010 Oct 13;170(2):503-13
pubmed: 20633606
Mov Disord. 2016 Apr;31(4):512-20
pubmed: 26898243
Nature. 1990 Sep 13;347(6289):146-51
pubmed: 1975644
Psychopharmacology (Berl). 2010 Jun;210(2):161-8
pubmed: 20333506
Prog Neurobiol. 2004 Dec;74(6):363-96
pubmed: 15649582
Curr Opin Pharmacol. 2007 Feb;7(1):100-5
pubmed: 17174156
Future Med Chem. 2014 Apr;6(5):485-7
pubmed: 24649950
Curr Opin Pharmacol. 2009 Feb;9(1):53-8
pubmed: 19138563
Mol Pharmacol. 2014 Oct;86(4):417-29
pubmed: 25097189
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109926
pubmed: 32171904
Neurosci Lett. 1993 May 28;155(1):92-5
pubmed: 8361670
Eur J Pharmacol. 2011 Jun 1;659(2-3):187-92
pubmed: 21466803
Trends Pharmacol Sci. 1989 Jun;10(6):230-5
pubmed: 2549665
Neurobiol Dis. 2013 Jun;54:339-48
pubmed: 23328768
Eur J Neurosci. 2004 May;19(9):2377-87
pubmed: 15128392
Neuroscience. 2005;136(2):381-6
pubmed: 16216425
Physiol Rev. 2009 Jan;89(1):73-120
pubmed: 19126755
Curr Opin Pharmacol. 2010 Feb;10(1):87-92
pubmed: 19837631
J Neurochem. 2009 Mar;108(6):1507-14
pubmed: 19166510
Annu Rev Neurosci. 2000;23:185-215
pubmed: 10845063
Mol Pharmacol. 2008 Jul;74(1):59-69
pubmed: 18424554
J Med Chem. 2005 May 19;48(10):3474-7
pubmed: 15887955
Eur J Med Chem. 2015 Aug 28;101:367-83
pubmed: 26164842
ChemMedChem. 2012 Mar 5;7(3):509-14
pubmed: 22213714
Annu Rev Neurosci. 1993;16:299-321
pubmed: 8460895
J Neurochem. 2008 Jul;106(2):560-77
pubmed: 18410503
J Neurochem. 2006 Sep;98(6):1866-75
pubmed: 16882311
Eur J Neurosci. 2005 Nov;22(10):2422-30
pubmed: 16307585
Cells. 2020 Jan 08;9(1):
pubmed: 31936298
Neuroscience. 1996 Jul;73(1):131-43
pubmed: 8783237
Annu Rev Pharmacol Toxicol. 2009;49:57-71
pubmed: 18834313
J Biol Chem. 2007 Dec 7;282(49):35842-54
pubmed: 17923483
Aging Dis. 2015 Oct 01;6(5):349-68
pubmed: 26425390
Kidney Int. 2008 Sep;74(6):750-9
pubmed: 18547994
J Neurosci. 2002 Oct 15;22(20):8785-9
pubmed: 12388584
Mov Disord. 2011 Oct;26 Suppl 3:S2-41
pubmed: 22021173
Nature. 1996 Feb 15;379(6566):606-12
pubmed: 8628395
Am J Psychiatry. 2016 Feb 1;173(2):107-11
pubmed: 26844792
CNS Neurol Disord Drug Targets. 2008 Nov;7(5):410-21
pubmed: 19128200
Curr Neuropharmacol. 2018 Jan 30;16(2):222-230
pubmed: 28521704
Eur Neuropsychopharmacol. 2013 Aug;23(8):799-813
pubmed: 23791072
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):596-600
pubmed: 20632968
Nat Rev Neurosci. 2001 Apr;2(4):274-86
pubmed: 11283750
FEBS Lett. 1996 Mar 4;381(3):257-61
pubmed: 8601467
J Neurochem. 2003 Nov;87(3):631-41
pubmed: 14535946
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8155-9
pubmed: 1518841
Biochem Pharmacol. 2019 May;163:154-168
pubmed: 30772268
Science. 2010 Nov 19;330(6007):1091-5
pubmed: 21097933
J Clin Endocrinol Metab. 2002 Dec;87(12):5545-52
pubmed: 12466351
Curr Opin Pharmacol. 2010 Feb;10(1):100-7
pubmed: 19896900
Lancet Neurol. 2013 Aug;12(8):747-55
pubmed: 23726851
Neuroscience. 1995 Apr;65(3):731-45
pubmed: 7609872
Brain Res. 1991 Nov 15;564(2):203-19
pubmed: 1839781
Neuropharmacology. 2009 Jan;56(1):237-46
pubmed: 18723036
Curr Med Chem. 2012;19(20):3353-87
pubmed: 22680630
Mol Pharmacol. 1999 Nov;56(5):1025-30
pubmed: 10531409
J Biol Chem. 2011 May 6;286(18):15641-51
pubmed: 21454669
J Pharmacol Exp Ther. 2010 Aug;334(2):556-65
pubmed: 20494958
Mol Pharmacol. 2012 Feb;81(2):175-88
pubmed: 22039094
Neural Regen Res. 2017 Jul;12(7):1068-1070
pubmed: 28852384
Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9050-5
pubmed: 15932946
J Neurosci. 1997 Jun 1;17(11):4282-92
pubmed: 9151745
J Biol Chem. 2001 Aug 10;276(32):30308-14
pubmed: 11373283
J Neurosci. 2000 Dec 1;20(23):8677-84
pubmed: 11102473
High Blood Press Cardiovasc Prev. 2020 Jun 23;:
pubmed: 32578165
Neural Plast. 2018 Feb 4;2018:4196961
pubmed: 29531524
Nature. 2000 Oct 26;407(6807):971-7
pubmed: 11069170
Eur Neuropsychopharmacol. 2015 Sep;25(9):1462-9
pubmed: 25532864
Mov Disord. 2015 Sep 15;30(11):1442-50
pubmed: 26208210
Int J Neuropsychopharmacol. 2010 Mar;13(2):181-90
pubmed: 19995481
Eur J Neurosci. 2008 Oct;28(7):1231-40
pubmed: 18973551
J Neurosci. 2005 Dec 7;25(49):11300-12
pubmed: 16339025
Nature. 1998 Dec 17;396(6712):679-82
pubmed: 9872316
Mol Neurobiol. 2018 Feb;55(2):1054-1067
pubmed: 28092083
Psychopharmacology (Berl). 2008 Mar;196(4):533-42
pubmed: 17985117
J Neurosci. 2006 Apr 26;26(17):4567-76
pubmed: 16641236
J Biol Chem. 1996 Jul 5;271(27):16384-92
pubmed: 8663163
Front Biosci. 2008 Jan 01;13:492-504
pubmed: 17981563
J Neurosci. 2006 Jul 5;26(27):7272-80
pubmed: 16822985
Stem Cells Dev. 2013 May 15;22(10):1522-40
pubmed: 23286225
Neurobiol Dis. 2019 Sep;129:1-12
pubmed: 31051233
Nat Med. 2003 Jun;9(6):762-7
pubmed: 12740572
Eur Neuropsychopharmacol. 2015 Sep;25(9):1470-9
pubmed: 25453482
Physiol Rev. 1998 Jan;78(1):189-225
pubmed: 9457173
Mol Pharmacol. 2013 Jun;83(6):1176-89
pubmed: 23543412
Bioorg Med Chem. 2008 Apr 1;16(7):3744-58
pubmed: 18282756
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S44-53
pubmed: 20123557
J Neurosci. 2005 Dec 7;25(49):11288-99
pubmed: 16339024
Nature. 1979 Mar 15;278(5701):252-4
pubmed: 423973
Neuropharmacology. 2007 Mar;52(3):985-94
pubmed: 17157884
J Biol Chem. 1999 Jul 2;274(27):19487-97
pubmed: 10383466
Pharmacol Rev. 1997 Sep;49(3):231-52
pubmed: 9311022
Mol Pharmacol. 1997 Sep;52(3):508-14
pubmed: 9281614
J Neurosci. 1993 Feb;13(2):596-604
pubmed: 7678857
Biochem Pharmacol. 2009 Oct 1;78(7):703-11
pubmed: 19481063
Int J Mol Sci. 2014 May 14;15(5):8570-90
pubmed: 24830558
J Neurosci. 2003 Jul 2;23(13):5693-7
pubmed: 12843272
Curr Top Med Chem. 2007;7(4):343-5
pubmed: 17305575
Mol Neurobiol. 2015 Dec;52(3):1408-1420
pubmed: 25344317
Trends Pharmacol Sci. 1993 Feb;14(2):43-9
pubmed: 8480373
Neuropsychopharmacology. 2007 Jan;32(1):35-42
pubmed: 16710311
J Neurochem. 2012 Mar;120(5):765-78
pubmed: 22145570
CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1101-13
pubmed: 24040823
J Neurosci. 2009 Jan 28;29(4):918-29
pubmed: 19176801